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Abstract 
Mitral stenosis (MS) is a condition which happened because of congenital or acquired event. The most 
common etiology of MS in Indonesia is Rheumatic Heart Disease (RHD). Chronic inflammation on the 
mitral valve could lead to stenosis from mild to severe degree. Mitral stenosis could lead to many 
complications such as pulmonary hypertension and atrial fibrillation (AF). The prevalence of AF in 
patients with MS is related to the severity of valve obstruction and patient age. AF event in patient 
with MS could be happen because of Left Atrial (LA) dilatation of the patient. The mechanism that 
responsible for AF in patient with MS is a complex one. AF even with or without atrial flutter episode 
could lead a deterioration of patient hemodynamic. In the other way, the patient also predisposes to 
left atrial thrombus formation and systemic embolic events. Good awareness in diagnosis and 
management of atrial fibrillation in patient with MS are mandatory to reduce the morbidity and 
mortality. 
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Abstrak 
Mitral stenosis (MS) adalah suatu kondisi yang terjadi karena kejadian bawaan atau didapat. Etiologi 
MS yang paling umum di Indonesia adalah Penyakit Jantung Rematik (PJR). Peradangan kronis pada 
katup mitral dapat menyebabkan stenosis dari derajat ringan ke berat. MS dapat menyebabkan 
banyak komplikasi seperti hipertensi paru dan Atrial Fibrilasi (AF). Prevalensi AF pada pasien dengan 
MS terkait dengan keparahan obstruksi katup dan usia pasien. Kejadian AF pada pasien dengan MS 
dapat terjadi karena dilatasi Left Atrial (LA) pasien. Mekanisme yang bertanggung jawab untuk AF 
pada pasien dengan MS adalah mekanisme yang kompleks. AF bahkan dengan atau tanpa episode 
atrium flutter dapat menyebabkan penurunan hemodinamika pasien. Dengan cara lain, pasien juga 
merupakan predisposisi untuk pembentukan trombus atrium kiri dan kejadian embolik sistemik. 
Kesadaran yang baik dalam diagnosis dan manajemen AF pada pasien dengan MS adalah wajib untuk 
mengurangi morbiditas dan mortalitas. 
Kata kunci: atrial fibrillation; atrial flutter; mitral stenosis; penyakit jantung rematik 
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INTRODUCTION 
Valvular heart disease accounts for 10% to 
20% of all cardiac surgical procedures in 
the United States. The primary causes of 
valve disease are age-associated calcific 
valve changes and inherited or congenital 
conditions. The prevalence of rheumatic 
valve disease now is very low in the United 
States and Europe because of primary 
prevention of rheumatic fever, although 
rheumatic valve disease remains prevalent 
in the developing world.1,2 
The combination of mitral valve disease 
and atrial inflammation secondary to 
rheumatic carditis causes left atrial 
dilation, fibrosis of the atrial wall, and 
disorganization of the atrial muscle 
bundles. These changes lead to disparate 
conduction velocities and inhomogeneous 
refractory periods. Premature atrial 
activation, caused by an automatic focus or 
re-entry, may stimulate the left atrium 
during the vulnerable period, thereby 
precipitating Atrial Fibrillation (AF).1,2 
This case illustration will be discussed 
about patient who was hospitalized with 
diagnosis atrial fibrillation with atrial 
flutter episode and severe mitral stenosis. 
CASE 
A-31 years old woman came to the ER of 
M. Djamil General Hospital with a chief 
complaint was palpitation since four days 
before admission. She felt a rapid and 
irregular heartbeat that happened on rest. 
She also had history of dizziness without 
syncope episode. She already had the 
same complaint 10 years ago but never 
seek any medical advice. 
The patient also had shortness of breath 
that became worse in the last four days 
ago. The complaints were becoming worse 
on activities that made her could not do 
her daily activities. She admitted that she 
had history of shortness of breath for 10 
years ago but hadn’t seek any medical 
advice too. She routinely slept with 2-3 
pillows for five years ago with history of 
sudden breathlessness on the middle of 
the night. History of ankle swollen was 
declined. On her childhood, she had history 
of recurrent upper respiratory tract 
infection. When she was on the fourth 
grade of elementary school, she had 
history of joint pain that migrating to the 
other joint and accompanied by high 
degree of fever. But she never seeks any 
medical consultation. The patient was 
referred from private hospital on Ujung 
Batu by family order without any referring 
letter.  
From physical examination were found 
that patient on moderate condition with 
alert of consciousness. Her blood pressure 
was 116/64 mmHg with heart rate 160-170 
bpm (beats per minute), respiratory rate 
24 times per minute. Her peripheral 
arterial saturation was 99% on four litres 
per minute nasal cannula. Her jugular vein 
pressure was 5+3 cmH2O. On chest 
examination were found that ictus cordis 
was palpated on 1 finger from left lower 
midclavicular is border on RIC VI. On 
auscultation were found an irregularly 
irregular heartbeat, with a murmur and 
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gallop were difficult to defined. On 
pulmonary examination were found fine 
bibasilar rales without wheezing.  
On electrocardiogram that were recorded 
in ER of M. Djamil General Hospital were 
found the atrial fibrillation rhythm with 
episode of atrial flutter with QRS rate 
about 160-170 bpm, left axis deviation, 
without change on ST-T segment as a 
figure below: 
On chest x-ray were found cardiomegaly 
with cardiothoracic ratio were 68% with 
prominent pulmonary segment, flattened 
cardiac waist with cranialization and 
infiltrate. 
On laboratory examination were found 
haemoglobin level 13.3 gr/dL, haematocrit 
38%, leukocyte 14.720/mm3, thrombocyte 
335.000/mm3. Sodium level was 138 
mEq/dl, potassium 4.5 mEq/dl, calcium 9.9 
mEq/dl and chloride 100 mEq/dl. AST was 
39 and ALT 26 mg/dl. Random blood 
glucose level was 100 mg/dl with urea 47 
and creatinine 0.7 with creatinine 
clearance 73 ml/min/1.73 m2. Her 
prothrombin time was 16.7 and APTT 44.2 
seconds with INR 1.4 IU. On blood gases 
analysis from vein sample were found that 
pH 7.39, pCO2 34 mmHg, pO2 44 mmHg, 
HCO3- 20.6, BE -4.4 and SpO2 79%.  Her 
HAS-BLED score was 0. 
Patient was diagnosed as AF RVR with atrial 
flutter episode et causa suspected mitral 
stenosis (MS) fc III et causa suspected 
rheumatic heart disease (RHD) with 
community acquired pneumonia (CAP). 
Patient had oxygenation with binasal 
cannula 4 lpm, IVFD RL 500cc/24 hours, 
digitalization with digoxin 0.25 mg iv. Four 
hours after digitalization the heart rate 
decreased to 110 bpm. After that the 
patient been given with heparin 4000 IU 
intravenous bolus that maintain with 720 
IU/hour iv. Patient also had warfarin 5 mg 
od (once daily), digoxin 0.25 mg od, 
furosemide 20 mg bid (iv) and RL 500cc/24 
hour. Patient also consulted to 
pulmonology department and was 
assessed as CAP and had ceftriaxone 2 g od 
(iv), n-acetylcysteine 300 mg bid (iv) and 
nebulization with salbutamol every six 
hour. Patient was planned to be performed 
echocardiography examination on the next 
day, and check PT, APTT, and INR because 
she was on heparinization. 
On the second day of hospitalization, the 
palpitation and shortness of breath were 
decreased. Her BP was 98/62 mmHg, HR 
was 96 bpm irregularly irregular, with RR 
20 time per minute. On physical 
examination were found mid-diastolic 
murmur grade III/IV and opening snap on 
apex. Her fluid balance was -150 cc/18 
hours with urine output was 0.95 
cc/kgBW/h. The therapy continued with 
UFH 720 IU/h (APTT 79.5 s). Patient were 
moved to cardiology Ward. 
On the third day patient was 
hemodynamically stable and had 
echocardiography with the result 
moderate-severe MS with MVA 0.8 cm2 
(planimetry) and 1.1 cm2 (VTI), moderate 
mitral regurgitation (MR) ec RHD (Wilkins 
score 9), mild aortic regurgitation (AR) ec 
RHD, moderate tricuspid regurgitation (TR) 
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with TVG 50 mmHg and high probability 
pulmonary hypertension (PH) with MPAP 
40 mmHg, good LV function (EF 62%), 
global normo kinetic, good RV contractility 
(TAPSE 1.8 cm), with SEC and thrombus in 
left atrium (LA) with minimal pericardial 
effusion on posterior wall. On this day 
patient was started to get bisoprolol 1.25 
mg od and warfarin were reduced to 2 mg 
od. On the fourth- and fifth-day patient 
was in a stable condition. She still had atrial 
fibrillation rhythm but in a normo 
ventricular response.  
On the sixth day patient was discharge with 
therapy bisoprolol 1x2.5 mg od, 
furosemide 40 mg od, warfarin 2 mg od. 
Patient were advised to control to 
outpatient cardiology clinic in M. Djamil 
General Hospital to be prepared to have 
mitral valve replacement surgery. 
DISCUSSIONS 
Were reported a-31 years old woman with 
diagnosis AF RVR with atrial flutter 
episode, MS NYHA fc III and CAP. Based on 
anamnesis, physical examination, 
electrocardiogram, and other modalities 
patient was diagnosed as atrial fibrillation 
because of mitral stenosis. Based on the 
literature, dyspnoea is the most common 
presenting symptoms of MS. Symptoms 
may be caused by a reduced ability to 
increase cardiac output normally with 
exercise or elevated pulmonary venous 
pressures and reduced pulmonary 
compliance.1 
Dyspnoea may be accompanied by cough 
and wheezing. Vital capacity is reduced, 
presumably because of the presence of 
engorged pulmonary vessels and 
interstitial oedema. Tachycardia that been 
resulted from exercise, pregnancy, 
hyperthyroidism, anaemia, infection, or 
AF. All these will make increase the rate of 
blood flow across the mitral orifice, 
resulting in further elevation of the left 
atrial pressure, and decrease the diastolic 
filling time, resulting in a reduction in 
forward cardiac output.1,2  
The most common findings on physical 
examination in patients with MS are an 
irregular pulse caused by AF and signs of 
left- and right-heart failure. Patients with 
severe chronic MS, a low cardiac output, 
and systemic vasoconstriction may exhibit 
the so-called mitral facies, characterized by 
pinkish-purple patches on the cheeks.1 In 
this patient had found irregularly irregular 
rhythm that cause by atrial fibrillation. 
When the heart rate was reduced to 
normal limit, on physical examination of 
the patient were found mid-diastolic 
murmur grade III/IV and opening snap. The 
diastolic, low-pitched, rumbling murmur of 
MS is best heard at the apex, with the bell 
of the stethoscope and with the patient in 
the left lateral recumbent position. 
Opening snap is a sharp, high-pitched 
sound, and its timing does not vary 
significantly with respiration. In mitral 
stenosis the OS is heard best between the 
apex and the left sternal border, just after 
the aortic closure sound (A2), when the left 
ventricular pressure falls below that of the 
left atrium.5,6,8 
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The ECG is relatively insensitive for 
detecting mild MS, but it does show 
characteristic changes in moderate or 
severe obstruction. Left atrial enlargement 
(LAE) is a principal electrocardiographic 
feature of MS and is found in 90% of 
patients with significant MS and sinus 
rhythm. The electrocardiographic signs of 
LAE correlate more closely with left atrial 
volume often regress after successful 
valvotomy. AF is common with 
longstanding MS, as noted.1,2 From the 
chest x-ray, patients with 
hemodynamically significant MS almost 
invariably have evidence of left atrial 
enlargement on the lateral and left 
anterior oblique views.1 
Echocardiography is the most accurate 
approach to the diagnosis and evaluation 
of MS. It is recommended for all patients 
with MS at initial presentation, for re-
evaluation of changing symptoms or signs, 
and at regular intervals (depending on 
disease severity) for monitoring disease 
progression. Imaging shows the 
characteristic anatomy with leaflet 
thickening and restriction of opening 
caused by symmetric fusion of the 
commissures, resulting in “doming” of the 
leaflets in diastole. As disease becomes 
more severe, thickening extends from the 
leaflet tips toward the base, with further 
restriction of motion and less curvature of 
the leaflet in diastole.1,9 
Mitral valve area is measured by direct 
planimetry from two-dimensional short-
axis images and calculated by the Doppler 
pressure half-time and PISA (proximal 
isovelocity surface area) methods. 
Evaluation of the morphology of the valve 
is helpful for predicting the hemodynamic 
results and outcome of percutaneous 
BMV. A mitral valve with a score less than 
8 to 9 with no more than moderate mitral 
regurgitation is deemed the best candidate 
for PBMV.10,11 From the echo result this 
patient had MVA 0.8 cm2 (planimetry) and 
1.1 cm2 (VTI) and her Wilkins score was 9. 
AF is the most common complication of 
MS. The prevalence of AF in patients with 
MS is related to the severity of valve 
obstruction and patient age. Even when MS 
is severe, the prevalence of AF is related to 
age. AF may precipitate or worsen 
symptoms caused by loss of the atrial 
contribution to filling and to a short 
diastolic filling period when the ventricular 
rate is not well controlled. In addition, AF 
predisposes affected patients to left atrial 
thrombus formation and systemic embolic 
events.1,2 
The mechanisms responsible for AF are 
complex. Triggering events may differ from 
maintenance mechanisms. In addition, the 
clinical phenotypes of paroxysmal, 
persistent, and longstanding persistent AF 
have different electrophysiologic 
characteristics because of remodeling and 
different clinical modulators that affect the 
substrate, such as heart failure, atrial 
stretch and ischemia, sympathovagal 
influences, inflammation, and fibrosis.12,13 
Atrial flutter occurs commonly in 
association with AF, and 3 of every 4 
patients with atrial flutter will, at some 
time, manifest clinical AF. The term atrial 
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flutter is generally used to describe atrial 
arrhythmias with large reentrant circuits. 
The surface ECG is characterized by regular 
repetitive flutter waves with an undulating 
baseline. Atrial flutter associated with 
chronic obstructive pulmonary disease, 
mitral or tricuspid valve disease, 
thyrotoxicosis, and postsurgical repair of 
certain congenital cardiac lesions, as well as 
enlargement of the atria for any reason, 
especially the right atrium.3,14 
Pulmonary hypertension in patients with 
MS results from the following: (1) passive 
backward transmission of the elevated left 
atrial pressure; (2) pulmonary arteriolar 
constriction, which presumably is triggered 
by left atrial and pulmonary venous 
hypertension (reactive pulmonary 
hypertension); and (3) organic obliterative 
changes in the pulmonary vascular bed, 
which may be considered to be a 
complication of longstanding and severe 
MS. In time, severe pulmonary 
hypertension results in right-sided heart 
failure, with dilation of the right ventricle 
and its annulus, secondary tricuspid 
regurgitation (TR), and sometimes 
pulmonic regurgitation.1,2 
In patients with severe MS, with persistent 
symptoms after intervention or when 
intervention is not possible, medical 
therapy with oral diuretics and the 
restriction of sodium intake may improve 
symptoms. Digitalis glycosides do not alter 
the hemodynamic and usually do not 
benefit patients with MS and sinus rhythm, 
but these drugs are of value in slowing the 
ventricular rate in patients with AF and in 
treating patients with right-sided heart 
failure. Hemoptysis is managed by 
measures designed to reduce pulmonary 
venous pressure, including sedation, 
assumption of the upright position, and 
aggressive diuresis. Beta-adrenergic 
blocking agents and rate-slowing calcium 
antagonists may increase exercise capacity 
by reducing heart rate in patients with sinus 
rhythm, especially in patients with AF.1,2 
Management of AF for patients with MS is 
similar to management for AF of any cause. 
However, it typically is more difficult to 
restore and maintain sinus rhythm because 
of pressure overload of the left atrium in 
conjunction with effects of the rheumatic 
process on atrial tissue and the conducting 
system. Immediate treatment of AF 
includes administration of intravenous 
heparin followed by oral warfarin. The 
ventricular rate should be slowed, initially 
with an intravenous beta blocker or 
nondihydropyridine calcium channel 
antagonist, followed by long-term rate 
control with oral doses of these agents. 
When these medications are ineffective or 
when additional rate control is necessary, 
digoxin or amiodarone may be considered. 
If cardioversion is planned in a patient who 
has had AF for more than 24 hours before 
the procedure, anticoagulation with 
warfarin for more than 3 weeks is 
indicated. Alternatively, if TEE results show 
no atrial thrombus, immediate 
cardioversion can be carried out provided 
the patient is effectively anticoagulated 
with intravenous heparin before and during 
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the procedure, and with warfarin 
chronically thereafter.1,2,4 
In patients who cannot be converted or 
maintained in sinus rhythm, digitalis should 
be used to maintain the ventricular rate at 
rest at approximately 60 beats/min. If this 
is not possible, small doses of a beta-
adrenergic blocking agent, such as atenolol 
(25 mg daily) or metoprolol (50 to 100 mg 
daily), may be added. Beta blockers are 
particularly helpful in preventing rapid 
ventricular responses that develop during 
exertion. Multiple repeat cardioversions 
are not indicated if the patient fails to 
sustain sinus rhythm while on adequate 
doses of an antiarrhythmic.4 
The optimal heart rate target in AF patients 
is unclear. The RACE (Rate Control Efficacy 
in Permanent Atrial Fibrillation) II study 
randomized 614 patients with permanent 
AF to either a target heart rate 80 bpm. at 
rest and 110 bpm. during moderate 
exercise, or to a lenient heart rate target of 
110 bpm.4 
Anticoagulant therapy is indicated for 
prevention of systemic embolism in 
patients with MS and AF (persistent or 
paroxysmal), any previous embolic events 
(even if in sinus rhythm) and documented 
left atrial thrombus.5 The target INR for 
patient who undertreatment with warfarin 
should be 2.0 to 3.0. This range of INRs 
provides the best balance between stroke 
prevention and haemorrhagic 
complications. Maintaining the INR at a 
level of 2.0 or higher is important because 
even a relatively small decrease in the INR 
from 2.0 to 1.7 more than doubles the risk 
for stroke.4,15 
The pulmonary venous hypertension 
should always be targeted at the underlying 
cause. In many patients, a reduction in left-
sided filling pressure will result in a 
reduction in pulmonary artery pressure. 
Emphasis should be placed on blood 
pressure control, volume management, 
and sodium restriction. No PAH-specific 
therapy is currently approved for the 
treatment of pulmonary venous 
hypertension. In the setting of left 
ventricular systolic dysfunction, both 
proteinoids and endothelin receptor 
antagonists have been studied and have 
failed to demonstrate a treatment benefit 
and may even be harmful.1,5 
Most patients with favourable valve 
anatomy currently undergo PMC; however, 
open commissurotomy may be preferred 
by experienced surgeons in young patients 
with mild-to-moderate MR.  In 
asymptomatic patients with MS, surgery is 
limited to those rare patients at high risk of 
complications and with contraindications 
to PMC.1,5 In this case, the patient should 
have mitral valve surgery because she had 
thrombus on her left atrium which is one of 
the contraindications to PMC. 
CONCLUSIONS 
Atrial fibrillation with atrial flutter episode 
in this patient might be happened because 
remodelling of her cardiac structure. The 
remodelling is the result from high 
pressure on left atrium because mitral 
stenosis. The patient had intravenous 
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digoxin administration for her atrial 
fibrillation then bisoprolol when her heart 
failure was treated. She also had 
anticoagulant for her AF and for thrombus 
on left atrium. Pulmonary hypertension 
that happened to her is a complication 
from mitral stenosis itself. So, we should 
treat the main cause from this disease. She 
should have mitral valve surgery as a 
definitive treatment, because she had a 
contraindication to PMC. 
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